Cargando…

mTOR activity in AIDS-related diffuse large B-cell lymphoma

BACKGROUND: Patients infected with HIV have a significantly increased risk of developing non–Hodgkin lymphomas despite the widespread use of HAART. To investigate mTOR pathway activity in acquired immunodeficiency syndrome (AIDS) related diffuse large B-cell lymphoma AR-DLBCL, we used immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Browne, Sara H., Diaz-Perez, Julio A., Preziosi, Michael, King, Charles C., Jones, George A., Jain, Sonia, Sun, Xiaoying, Reid, Erin G., VandenBerg, Scott, Wang, Huan-You
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5305194/ https://www.ncbi.nlm.nih.gov/pubmed/28192480 http://dx.doi.org/10.1371/journal.pone.0170771

Ejemplares similares

Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
por: Dittmer, Dirk P, et al.
Publicado: (2012)

Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma
por: Mazan-Mamczarz, Krystyna, et al.
Publicado: (2015)

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
por: Ezell, Scott A., et al.
Publicado: (2016)

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
por: Argyriou, Pinelopi, et al.
Publicado: (2012)

mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
por: Xu, Wendan, et al.
Publicado: (2022)

miR‐155‐regulated mTOR and Toll‐like receptor 5 in gastric diffuse large B‐cell lymphoma
por: Huang, Wei‐Ting, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas
por: Rivera-Soto, Ricardo, et al.
Publicado: (2021)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
por: Majchrzak, Agata, et al.
Publicado: (2014)

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
por: Mallya, Sharmila, et al.
Publicado: (2014)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Caro-Vegas, Carolina, et al.
Publicado: (2019)

MDSCs participate in the pathogenesis of diffuse pulmonary hemorrhage in murine lupus through mTOR-FoxO1 signaling
por: Tan, Liping, et al.
Publicado: (2022)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Mechanical Stimulation Induces mTOR Signaling via an ERK-Independent Mechanism: Implications for a Direct Activation of mTOR by Phosphatidic Acid
por: You, Jae Sung, et al.
Publicado: (2012)

A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
por: Fukamachi, Hiroshi, et al.
Publicado: (2019)

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
por: Yuan, RuiRong, et al.
Publicado: (2009)

mTOR Overactivation in Mesenchymal cells Aggravates CCl(4)− Induced liver Fibrosis
por: Shan, Lanlan, et al.
Publicado: (2016)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR
por: Lin, Luhui, et al.
Publicado: (2020)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging
por: Węsierska-Gądek, Józefa
Publicado: (2010)

Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
por: Gipson, Tanjala T., et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
por: Umanah, George K. E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tlks2b6svti658rlahvpe8uavq